Predicted pathogenic germline mutations (Supplementary Fig. 2c) in BRCA1 and BRCA2 were identified in 1.36% and 1.64% of the cohort, respectively, and 2.22% of tumours harboured pathogenic CHEK2 germline mutations. The gene discussed is BRCA1; the disease is neoplasm.